Pluri (PLUR) Financials: History & Chart

Pluri Inc.(PLUR)

Biotechnology · Haifa, HA

$1.00-0.03 (-3.38%)

Delayed quote: Oct 6, 2026, 2:49 PM EDT

About Pluri Inc.

Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.

Haifa, HA

92 employees

www.pluri-biotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yaacov Yanay

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.02M	335K	167K	198K	316K	398K	427K	185K	326K
Cost of Goods Sold	563K	-120K	111K	241K	331K	191K	291K	74K	126K
Gross Profit	453K	455K	56K	-43K	-15K	207K	136K	111K	200K
Gross Profit Margin	44.6%	135.8%	33.5%	-21.7%	-4.7%	52.0%	31.9%	60.0%	61.3%
Total Operating Expenses	25.02M	5.62M	6.61M	6.46M	6.33M	6.83M	5.54M	5.07M	5.40M
Research & Development	15.14M	3.37M	3.98M	3.83M	3.96M	3.99M	3.04M	2.92M	2.89M
Selling, General & Administrative	9.92M	2.25M	2.63M	2.64M	2.40M	2.83M	2.49M	2.14M	2.51M
Operating Income (EBIT)	-24.95M	-5.55M	-6.55M	-6.51M	-6.35M	-6.62M	-5.40M	-4.96M	-5.20M
Operating Margin	-2455.9%	-1655.5%	-3922.2%	-3285.9%	-2009.5%	-1663.6%	-1264.6%	-2679.5%	-1594.5%
Income Before Tax (EBT)	-25.39M	-6.19M	-6.17M	-6.88M	-6.14M	-7.77M	-6.33M	-3.11M	-6.04M
Interest Income	488K	73K	104K	118K	193K	312K	260K	251K	321K
Interest Expense	932K	235K	237K	231K	229K	233K	212K	211K	217K
Other Income/Expense	-434K	-648K	378K	-374K	210K	-1.15M	-935K	1.85M	-838K
Net Income	-24.45M	-5.88M	-6.17M	-6.54M	-5.85M	-7.60M	-6.15M	-2.96M	-5.88M
Income Tax Expense	-17K	-1K	0.00	-8K	-8K	-5K	0.00	0.00	0.00
Net Profit Margin	-2406.0%	-1755.2%	-3695.8%	-3304.5%	-1851.3%	-1909.0%	-1439.6%	-1597.8%	-1804.3%
EBITDA	-24.44M	-5.42M	-6.42M	-6.38M	-6.22M	-6.51M	-5.33M	-4.89M	-5.13M
EBITDA Margin	-2405.6%	-1618.5%	-3845.5%	-3220.7%	-1968.4%	-1635.7%	-1247.8%	-2642.7%	-1574.5%
Depreciation & Amortization	511K	124K	128K	129K	130K	111K	72K	68K	65K
EPS Basic	-2.45	-0.54	-0.55	-0.71	-0.65	-0.96	-1.14	-0.53	-1.12
EPS Diluted	-2.45	-0.54	-0.55	-0.71	-0.65	-0.96	-1.14	-0.53	-1.12
Weighted Average Basic Shares	10.82M	10.82M	10.05M	9.26M	9.00M	7.89M	5.55M	5.55M	5.24M
Weighted Average Diluted Shares	10.82M	10.82M	10.05M	9.26M	9.00M	7.89M	5.55M	5.55M	5.24M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	06/30/2026	06/30/2025	06/30/2024	06/30/2023	06/30/2022	06/30/2021	06/30/2020	06/30/2019
Revenue	1.02M	1.34M	326K	287K	234K	0.00	23K	54K
Cost of Goods Sold	563K	682K	4K	9K	1.05M	1.37M	1.57M	2K
Gross Profit	453K	654K	322K	278K	-819K	-1.37M	-1.55M	52K
Gross Profit Margin	44.6%	49.0%	98.8%	96.9%	-350.0%	N/A	-6726.1%	96.3%
Total Operating Expenses	25.39M	22.83M	22.48M	27.52M	40.77M	49.25M	27.93M	35.58M
Research & Development	15.31M	12.85M	12.45M	15.74M	24.38M	30.07M	20.12M	24.59M
Selling, General & Administrative	10.30M	9.98M	10.03M	11.78M	17.45M	20.56M	7.80M	9.16M
Operating Income (EBIT)	-24.94M	-22.18M	-22.16M	-27.25M	-41.59M	-50.62M	-29.48M	-35.53M
Operating Margin	-2454.5%	-1659.9%	-6796.9%	-9493.4%	-17774.8%	N/A	-128156.5%	-65800.0%
Income Before Tax (EBT)	-25.37M	-23.25M	-21.34M	-28.89M	-41.37M	-49.87M	-29.15M	-35.31M
Interest Income	488K	1.14M	1.31M	1.08M	581K	492K	384K	385K
Interest Expense	-932K	873K	866K	843K	887K	78K	196K	29K
Other Income/Expense	-456K	-1.08M	814K	-1.64M	219K	758K	324K	225K
Net Income	-23.82M	-22.58M	-20.89M	-28.32M	-41.24M	-49.87M	-29.15M	-35.31M
Income Tax Expense	-25K	-5K	0.00	0.00	0.00	0.00	0.00	-94K
Net Profit Margin	-2344.6%	-1690.3%	-6407.4%	-9867.9%	-17624.8%	N/A	-126747.8%	-65383.3%
EBITDA	-24.43M	-21.86M	-21.91M	-26.88M	-40.54M	-49.25M	-27.91M	-33.57M
EBITDA Margin	-2404.2%	-1636.2%	-6719.3%	-9367.2%	-17324.8%	N/A	-121330.4%	-62166.7%
Depreciation & Amortization	511K	316K	253K	362K	1.05M	1.37M	1.57M	1.96M
EPS Basic	-2.44	-3.56	-3.99	-6.18	-10.24	-14.19	-12.80	-23.20
EPS Diluted	-2.44	-3.56	-3.99	-6.18	-10.24	-14.19	-12.80	-23.20
Weighted Average Basic Shares	9.74M	6.34M	5.24M	4.58M	4.02M	3.51M	2.27M	1.54M
Weighted Average Diluted Shares	9.74M	6.34M	5.24M	4.58M	4.02M	3.51M	2.27M	1.54M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.